



## Register of Interests (Board Members)

<b>Board Member's Name:</b>		Dr Tracy Cunningham	
<b>Date Appointed to the Board of the HRB</b>		15 July 2019	
<b>End of term on the Board of the HRB</b>		14 July 2024	
<b>Date of completion of register entry</b>	29 April 2022	<b>Date of most recent revision/update of register entry</b>	31 Jan 2023

### ***PART A - close colleagues***

*The term 'close colleagues' is defined as colleagues with whom the member of the Board / Board Committee has a close current or recent (covering at least the past 10 years) working partnership. It may be described in terms of college, faculty, department, or research group, and may include individuals or groups within or across institutions.*

*Where the conflict of Interest involves 'close colleagues' the member of the Board / Board Committee will not have access to documents, will not take part in discussions and will not take part in decisions*

#### **Please describe your 'close colleagues'**

I work in the pharmaceutical industry – for the last 6 years predominantly in the development of new medicines or new indications for approved medicines. I would consider Amryt Pharma (employed since April 2020) and AstraZeneca (Feb 2016- March 2020) employees as close colleagues.

In addition, I would consider Curran Scientific and the UCD dermatology research group as close colleagues as we are in a research partnership under a Disruptive Technology Innovative Fund (DTIF), non-viral gene therapy for dystrophic epidermolysis bullosa.

Note: In AstraZeneca, I worked in late-stage development global oncology, hematology and a rare associated condition of neurofibromatosis type 1, based in Cambridge UK. My close colleagues were outside Ireland and none of the clinical studies involved Irish institutions or individuals.

**PART B – Wider Community**

*Defined as the wider community for which the Board /Board Committee member might reasonably be considered to have shared interests or loyalty. The wider community may be interpreted to include current or previous (covering at least the past ten years) place of employment, colleagues and others who share business/ research interests (e.g., cancer prevention or obesity).*

*Where the conflict of Interest involves ‘wider community’ the Board/Board Committee member may not have access to documents, take part in discussions or take part in decisions. A final decision in respect of specific items of Board/Board Committee business will be made by the Chairperson, normally after consultation with the member.*

**Please describe your ‘wider community’**

I have an interest in research in rare diseases most specifically in epidermolysis bullosa and would consider the Irish patient advocacy group, Debra as part of my wider community.

**Part C – Domains of business/research**

*Domains of business/research in which the Board / Board Committee member is actively involved. Domains may be defined in terms of topics or methods/methodology. Depending on the context, this may be narrower or broader*

*Where the conflict of interest involves ‘Domains of business/research’ the Board/Board Committee member would take part in general discussions in these areas but would not take part in formal decisions relating to funding streams the specifically focus on these areas.*

**Please describe your ‘Domains of business/research’.**

My domains of research are oncology/haematology and rare diseases with a focus on registration studies to develop new medicines.

**Reviewed and approved by**

DocuSigned by:  
  
Signature: \_\_\_\_\_  
Prof Bernie Hannigan, Chairperson of the HRB.  
Date: 02 March 2023  
\_\_\_\_\_